EA199700185A1 - Способ уменьшения риска вертебральных переломов - Google Patents

Способ уменьшения риска вертебральных переломов

Info

Publication number
EA199700185A1
EA199700185A1 EA199700185A EA199700185A EA199700185A1 EA 199700185 A1 EA199700185 A1 EA 199700185A1 EA 199700185 A EA199700185 A EA 199700185A EA 199700185 A EA199700185 A EA 199700185A EA 199700185 A1 EA199700185 A1 EA 199700185A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fractures
verbal
risk
reducing
alendronate
Prior art date
Application number
EA199700185A
Other languages
English (en)
Other versions
EA000348B1 (ru
Inventor
Дэвид Б. Карпф
Томас П. Капидзи
Хю Кван
Артур К. II Сантора
Эшли Дж. Уэйтс
Original Assignee
Мерк Энд Ко., Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Энд Ко., Инк. filed Critical Мерк Энд Ко., Инк.
Publication of EA199700185A1 publication Critical patent/EA199700185A1/ru
Publication of EA000348B1 publication Critical patent/EA000348B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Алендронат, бисфосфонат при ежедневном введении в течение значительного периода времени обладает способностью снижать уровень вертебральных переломов у женщин, находящихся в постклимактерическом периоде. Он может снижать число и тяжесть переломов. Введение алендроната может также предупреждать деформирование позвоночника и уменьшение роста.
EA199700185A 1995-02-17 1996-02-13 Способ уменьшения риска вертебральных переломов EA000348B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/389,860 US20010051616A1 (en) 1995-02-17 1995-02-17 Method of lessening the risk of vertebral fractures
PCT/US1996/001946 WO1996025166A1 (en) 1995-02-17 1996-02-13 Method of lessening the risk of vertebral fractures

Publications (2)

Publication Number Publication Date
EA199700185A1 true EA199700185A1 (ru) 1997-12-30
EA000348B1 EA000348B1 (ru) 1999-04-29

Family

ID=23540050

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199700185A EA000348B1 (ru) 1995-02-17 1996-02-13 Способ уменьшения риска вертебральных переломов

Country Status (14)

Country Link
US (1) US20010051616A1 (ru)
EP (1) EP0809503A4 (ru)
JP (1) JPH11501906A (ru)
KR (1) KR19980702209A (ru)
CN (1) CN1181008A (ru)
AU (1) AU689379B2 (ru)
CA (1) CA2213076A1 (ru)
EA (1) EA000348B1 (ru)
HU (1) HUP9802077A3 (ru)
NZ (1) NZ303476A (ru)
PL (1) PL321836A1 (ru)
SK (1) SK111697A3 (ru)
WO (1) WO1996025166A1 (ru)
ZA (1) ZA961234B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
WO2000028982A2 (en) * 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
HUP0402267A3 (en) * 2001-12-21 2007-05-29 Procter & Gamble Method for treatment of bone disorders
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
BR0215413A (pt) * 2001-12-24 2004-12-14 Teva Pharma Formula dosada com um comprimido central de ingrediente ativo encapado em uma capa anular prensada de material em pó ou granulado e processo e conjunto de ferramentas para a sua produção
SI1880744T1 (sl) * 2002-05-10 2015-04-30 F. Hoffmann-La Roche Ag Bifosfonske kisline za zdravljenje in prepreäśevanje osteoporoze
ES2530791T3 (es) 2002-12-20 2015-03-05 Hoffmann La Roche Formulación de ibandronato de altas dosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
EP0600834A1 (en) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery

Also Published As

Publication number Publication date
MX9706275A (es) 1997-11-29
HUP9802077A2 (hu) 2000-06-28
EP0809503A4 (en) 2001-12-05
CN1181008A (zh) 1998-05-06
AU689379B2 (en) 1998-03-26
WO1996025166A1 (en) 1996-08-22
EP0809503A1 (en) 1997-12-03
KR19980702209A (ko) 1998-07-15
JPH11501906A (ja) 1999-02-16
HUP9802077A3 (en) 2001-10-29
SK111697A3 (en) 1998-02-04
NZ303476A (en) 2000-07-28
US20010051616A1 (en) 2001-12-13
EA000348B1 (ru) 1999-04-29
CA2213076A1 (en) 1996-08-22
ZA961234B (en) 1996-08-27
PL321836A1 (en) 1997-12-22
AU4979996A (en) 1996-09-04

Similar Documents

Publication Publication Date Title
EP0830138A4 (en) USE OF FIBROBLAST GROWTH FACTORS TO STIMULATE BONE GROWTH
ZA964816B (en) Implant for the surgical treatment of a vertebral isthmus fracture.
CA2184916A1 (en) Use of fibroblast growth factors to stimulate bone growth
FR2705235B1 (fr) Utilisation de particules d'un sel de calcium biocompatible et biorésorbable comme ingrédient actif dans la préparation d'un médicament destiné au traitement local des maladies déminéralisantes de l'os.
CA2262269A1 (en) Treatment of skeletal disorders
PL341112A1 (en) Methods of providing postmenopausal treatment to female patients using very low doses of oestrogen
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
EP0748634A3 (de) Implantat, seine Verwendung in der Chirurgie und Verfahren zu seiner Herstellung
AU1432795A (en) Devices and methods for posterior spinal fixation
NO952131L (no) Fremgangsmåte for behandling av et kirurgisk metallimplantat
EA199700183A1 (ru) Способ уменьшения риска невертебральных переломов костей
EA199700185A1 (ru) Способ уменьшения риска вертебральных переломов
MX9703944A (es) Metodo para usar derivados de triaril-etileno en el tratamiento y prevencion de osteoporosis.
AU7357596A (en) Surgical system and method for the reattachment of soft tiss ue to bone
EP0744176A3 (en) Methods for inhibiting bone loss
AU2534595A (en) Angiotensin ii for improving fertilization
EP0779812A4 (en) METHOD FOR TREATING OSTEOPOROSIS USING BONE-ACTIVE PHOSPHONATES AND PARATHORMONE
EP0841878A4 (en) DENTAL IMPLANT DEVICE
EP0828507A4 (en) METHOD FOR TREATING PAIN
AU3607293A (en) Implant therapy for bone growth stimulation
EP0904094A4 (en) TREATMENT OF BONE DISEASES USING ADRENOMEDULLINE
IL126158A0 (en) Method for treating substance abuse
CA2177595A1 (en) Metallic implant and process for treating a metallic implant
UA29186A (ru) Способ лечения постменопаузального остеопороза
TH24700A (th) " วิธีการลดความเสี่ยงของการแตกหักกระดูกสันหลังและที่ไม่เป็นกระดูกสันหลัง "

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ KG TJ TM RU